Design and synthesis of novel furan, furo[2,3-d]pyrimidine and furo[3,2-e][1,2,4]triazolo[1,5-c]pyrimidine derivatives as potential VEGFR-2 inhibitors
作者:Menna M.A. Abd El-Mageed、Amal A.M. Eissa、Awatef El-Said Farag、Essam Eldin A. Osman
DOI:10.1016/j.bioorg.2021.105336
日期:2021.11
Novel furan 6a-c, furo[2,3-d]pyrimidine 7a-f, 9, 10a-f, 12a,b, 14a-d and furo[3,2-e][1,2,4]triazolo[1,5-c]pyrimidine 8a-f derivatives were designed based on their structural similarity to a previously described oxazole VEGFR-2 back pocket binding fragment. The designed compounds were synthesized and screened for their in vitro VEGFR-2 inhibitory activity where they exhibited good to moderate nanomolar
新颖呋喃6A-C ,呋喃并[2,3- d ]嘧啶7A-F ,9,图10A-F ,图12A,B,14A-d和呋喃并[3,2- ë ] [1,2,4]三唑并[ 1,5 - c ]嘧啶8a-f衍生物是基于它们与先前描述的恶唑VEGFR-2后袋结合片段的结构相似性而设计的。合成并筛选设计的化合物的体外VEGFR-2 抑制活性,其中它们表现出良好到中等的纳摩尔抑制,并具有提高的配体效率。8b和10c (IC 50= 38.72 ± 1.7 和 41.40 ± 1.8 nM)与索拉非尼等效,6a、6c、7f、8a、8c、10b、10f、12b、14c和14d显示出良好的活性(IC 50 = 483M)。进一步评估了呋喃三唑并嘧啶8a-c和呋喃嘧啶衍生物10c对人脐静脉内皮细胞 (HUVEC) 的体外抗增殖活性,其中8b显示出比索拉非尼更高的效力并导致细胞周期停滞在 G2/M 期,而8c显示出良好的抗增殖作用G1